Market Fallers: Rio Tinto plc & GlaxoSmithKline plc

Rio Tinto Plc
[shareaholic app="share_buttons" id_name="post_below_content"]

The trading price for Rio Tinto plc EPIC code: LON:RIO has dropped -2.05% or -74.5 points throughout today’s trading session so far. Traders have so far given a mostly negative outlook throughout the trading session. The periods high has reached 3630 dropping as low as 3552. Volume total for shares traded during this period was 1,241,509 whilst the daily average number of shares exchanged is just 4,659,806. A 52 week share price high is 4541 around 912 points in difference to the previous days close of business and a 52 week low sitting at 3399 is a variance of 230 points. Rio Tinto plc has a 20 SMA of 3886.78 with a 50 day simple moving average now at 3842. The market capitalisation currently stands at £61,934.72m at the time of this report. The share price is in GBX. Mcap is measured in GBP. This article was written with the last trade for Rio Tinto plc being recorded at Tuesday, November 27, 2018 at 12:51:37 PM GMT with the stock price trading at 3554.5 GBX.

 

Shares of GlaxoSmithKline plc company symbol: LON:GSK has slid -1.42% or -22.4 points in today’s trading session so far. Sellers were far from a positive bunch during the session. Range high for the period has seen 1575.8 meanwhile the session low reached 1547.8. Volume total for shares traded at this point reached 2,297,339 while the daily average number of shares exchanged is 9,995,648. The 52 week high for the shares is 1631.13 which comes in at 56.73 points difference from the previous close and the 52 week low at 1179.39 is a variance of 395.01 points. GlaxoSmithKline plc now has a 20 simple moving average of 1567.08 and also a 50 day simple moving average now at 1541.96. Market capitalisation for the company is £78,086.43m at the time of this report. The stock is traded in GBX. Mcap is measured in GBP. This article was written with the last trade for GlaxoSmithKline plc being recorded at Tuesday, November 27, 2018 at 12:51:37 PM GMT with the stock price trading at 1552 GBX.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    GSK's Arexvy vaccine receives approval in Japan to protect adults aged 50-59 at increased risk from severe RSV infection, expanding its coverage.
    GSK Plc reports Q3 2024 results with strong growth in Specialty Medicines offsetting lower Vaccine sales. Core earnings rose by 5%, despite Zantac charges.
    GSK's new antibiotic gepotidacin earns FDA's Priority Review, marking potential first new uUTI oral treatment in 20 years, with decision due March 2025.

      Search

      Search